214 related articles for article (PubMed ID: 36838813)
1. Interaction of Camptothecin Anticancer Drugs with Ribosomal Proteins L15 and L11: A Molecular Docking Study.
Bailly C; Vergoten G
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838813
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
Sorensen M; Sehested M; Jensen PB
Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
[TBL] [Abstract][Full Text] [Related]
3. Computational Study of Anticancer Drug Resistance Caused by 10 Topisomerase I Mutations, Including 7 Camptothecin Analogs and Lucanthone.
Mulholland K; Wu C
J Chem Inf Model; 2016 Sep; 56(9):1872-83. PubMed ID: 27564845
[TBL] [Abstract][Full Text] [Related]
4. [Elucidation of the Mechanism of Topotecan-induced Antitumor Immune Activation].
Kitai Y
Yakugaku Zasshi; 2022; 142(9):911-916. PubMed ID: 36047216
[TBL] [Abstract][Full Text] [Related]
5. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.
Bailly C; Lansiaux A; Dassonneville L; Demarquay D; Coulomb H; Huchet M; Lavergne O; Bigg DC
Biochemistry; 1999 Nov; 38(47):15556-63. PubMed ID: 10569939
[TBL] [Abstract][Full Text] [Related]
6. Activity of Topotecan toward the DNA/Topoisomerase I Complex: A Theoretical Rationalization.
Bali SK; Marion A; Ugur I; Dikmenli AK; Catak S; Aviyente V
Biochemistry; 2018 Mar; 57(9):1542-1551. PubMed ID: 29412654
[TBL] [Abstract][Full Text] [Related]
7. Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.
Lansiaux A; Léonce S; Kraus-Berthier L; Bal-Mahieu C; Mazinghien R; Didier S; David-Cordonnier MH; Hautefaye P; Lavielle G; Bailly C; Hickman JA; Pierré A
Mol Pharmacol; 2007 Aug; 72(2):311-9. PubMed ID: 17494837
[TBL] [Abstract][Full Text] [Related]
8. Identification of RPL15 60S Ribosomal Protein as a Novel Topotecan Target Protein That Correlates with DAMP Secretion and Antitumor Immune Activation.
Yamada S; Kitai Y; Tadokoro T; Takahashi R; Shoji H; Maemoto T; Ishiura M; Muromoto R; Kashiwakura JI; Ishii KJ; Maenaka K; Kawai T; Matsuda T
J Immunol; 2022 Jul; 209(1):171-179. PubMed ID: 35725272
[TBL] [Abstract][Full Text] [Related]
9. An overview of topoisomerase I-targeting agents.
Arbuck SG; Takimoto CH
Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
[TBL] [Abstract][Full Text] [Related]
10. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Philippart P; Harper L; Chaboteaux C; Decaestecker C; Bronckart Y; Gordover L; Lesueur-Ginot L; Malonne H; Lavergne O; Bigg DC; da Costa PM; Kiss R
Clin Cancer Res; 2000 Apr; 6(4):1557-62. PubMed ID: 10778989
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor effects and mechanism of a novel camptothecin derivative YCJ100.
Zhang M; Fu W; Zhu LZ; Liu XF; Li L; Peng LZ; Kai GY; Liu YQ; Zhang ZJ; Xu CR
Life Sci; 2022 Dec; 311(Pt A):121105. PubMed ID: 36272467
[TBL] [Abstract][Full Text] [Related]
12. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan.
Subramanian D; Muller MT
Oncol Res; 1995; 7(9):461-9. PubMed ID: 8835290
[TBL] [Abstract][Full Text] [Related]
13. Insight on the Interaction between the Camptothecin Derivative and DNA Oligomer Mimicking the Target of Topo I Inhibitors.
Bocian W; Naumczuk B; Urbanowicz M; Sitkowski J; Bednarek E; Wiktorska K; Pogorzelska A; Wielgus E; Kozerski L
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296539
[TBL] [Abstract][Full Text] [Related]
14. Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo.
Huang M; Gao H; Chen Y; Zhu H; Cai Y; Zhang X; Miao Z; Jiang H; Zhang J; Shen H; Lin L; Lu W; Ding J
Clin Cancer Res; 2007 Feb; 13(4):1298-307. PubMed ID: 17287296
[TBL] [Abstract][Full Text] [Related]
15. Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan.
Danks MK; Garrett KE; Marion RC; Whipple DO
Cancer Res; 1996 Apr; 56(7):1664-73. PubMed ID: 8603418
[TBL] [Abstract][Full Text] [Related]
16. Action models for the antitumor drug camptothecin: formation of alkali-labile complex with DNA and inhibition of human DNA topoisomerase I.
Streltsov SA
J Biomol Struct Dyn; 2002 Dec; 20(3):447-54. PubMed ID: 12437383
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
[TBL] [Abstract][Full Text] [Related]
18. Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I - DNA complex.
Mancini G; D'Annessa I; Coletta A; Sanna N; Chillemi G; Desideri A
PLoS One; 2010 Jun; 5(6):e10934. PubMed ID: 20532182
[TBL] [Abstract][Full Text] [Related]
19. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.
Tanizawa A; Fujimori A; Fujimori Y; Pommier Y
J Natl Cancer Inst; 1994 Jun; 86(11):836-42. PubMed ID: 8182764
[TBL] [Abstract][Full Text] [Related]
20. Two novel camptothecin derivatives inhibit colorectal cancer proliferation via induction of cell cycle arrest and apoptosis in vitro and in vivo.
Du H; Huang Y; Hou X; Quan X; Jiang J; Wei X; Liu Y; Li H; Wang P; Zhan M; Ai X; Lu L; Yuan S; Sun L
Eur J Pharm Sci; 2018 Oct; 123():546-559. PubMed ID: 30118848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]